Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of p53 in cancer drug resistance and targeted chemotherapy.

Oncotarget - 31 Jan 2017

Hientz Karin, Mohr André, Bhakta-Guha Dipita, Efferth Thomas

Abstract excerpt

Cancer has long been a grievous disease complicated by innumerable players aggravating its cure. Many clinical studies demonstrated the prognostic relevance of the tumor suppressor protein p53 for many human tumor types. Overexpression of mutated p53 with reduced or abolished function is often connected to resistance to standard medications, including cisplatin, alkylating agents (temozolomide), anthracyclines,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Protein Conformation

Share to Proto-Oncogene Proteins c-mdm2

Share to Structure-Activity Relationship

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 27888811
DOI: 10.18632/oncotarget.13475
PMCID: PMC5352454

Genes

MDM2
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of p53 in cancer drug resistance and targeted chemotherapy.PMID 27888811Read ↗

Chemical Variations on the p53 Reactivation ThemeSemantic proximity Read ↗

p53 as a target for the treatment of cancer.Semantic proximity Read ↗

Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be AddressedSemantic proximity Read ↗

Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer AgentsSemantic proximity Read ↗

p53: from understanding its structure to advances in therapeutic targeting.Semantic proximity Read ↗

p53–Mdm2 inhibitors: patent review (2009 – 2010)Semantic proximity Read ↗

An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.Semantic proximity Read ↗

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trialsSemantic proximity Read ↗

Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicineSemantic proximity Read ↗

Towards the overcoming of anticancer drug resistance mediated by p53 mutations.Semantic proximity Read ↗

Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic StrategiesSemantic proximity Read ↗

Natural Modulators of the TP53 Pathway: Potential Herbal and Plant-Derived Agents for Cancer Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.